GS24-B025
/ GeneScience
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 18, 2026
GS24-B025, a novel CDH17- and CEA-directed bispecific antibody-drug conjugate, for the treatment of colorectal cancer
(AACR 2026)
- "These data suggest the potential of GS24-B025 as an effective treatment option for CRC patients and support its further evaluation in IND-enabling studies."
ADC • Bispecific • Colorectal Cancer • Oncology • Solid Tumor • CDH17 • CEACAM5
October 13, 2025
GS24-B025, a highly differentiated CDH17- and CEA-directed bispecific antibody-drug conjugate (bsADC), for the treatment of colorectal cancer
(AACR-NCI-EORTC 2025)
- "These preclinical data suggest the potential of GS24-B025 as an effective treatment option for CRC patients and support its further evaluation in IND-enabling studies."
Colorectal Cancer • Oncology • Solid Tumor • CDH17 • CEACAM5
1 to 2
Of
2
Go to page
1